US2023079121A1PendingUtilityA1

Repair and/or reconstitution of invertebral discs

81
Assignee: MESOBLAST INCPriority: Aug 6, 2007Filed: Jul 28, 2022Published: Mar 16, 2023
Est. expiryAug 6, 2027(~1.1 yrs left)· nominal 20-yr term from priority
Inventors:Peter Ghosh
A61K 35/12A61K 31/726A61P 19/08A61L 2430/38A61L 27/52A61L 27/3856A61L 27/3834A61K 31/727A61K 31/737A61K 35/28A61K 47/36A61P 19/04A61P 25/04A61P 25/02A61K 2035/124A61P 25/00C12N 2501/905A61K 9/4866A61P 21/00A61K 2300/00A61P 1/04A61K 31/728A61K 35/545C12N 5/0663A61K 38/14A61P 19/02A61P 29/00A61P 43/00A61P 17/06A61P 19/00
81
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention relates to a method for repair and reconstitution of invertebral discs in a subject which involves administration of STRO-1′ multipotent cells. The method of the invention is useful in the treatment of spinal conditions characterized by degeneration of the invertebral disc.

Claims

exact text as granted — not AI-modified
1 . A method for treating low back pain caused by a degenerated intervertebral disc in a human subject, the method comprising administering into the intervertebral disc space of the degenerated intervertebral disc a therapeutically effective amount of a composition comprising a culture-expanded population of allogeneic human cells enriched for non-hematopoietic, TNAP+multipotential cells and/or progeny cells thereof, wherein the population of human cells is substantially free of CD34+ cells. 
     
     
         2 - 4 . (canceled) 
     
     
         5 . The method according to  claim 1  further comprising administering to the intervertebral disc space a glycosaminoglycan (GAG). 
     
     
         6 . The method according to  claim 5  wherein the GAG is selected from the group consisting of hyaluronic acid (HA), chondroitan sulfate, dermatan sulfate, keratan sulfate, heparin, heparin sulfate, and galactosaminoglycuronglycan sulfate (GGGS). 
     
     
         7 . The method according to  claim 1  wherein six months after the administration the disc height index (DHI) of the subject's intervertebral disc is greater than the DHI of the subject's intervertebral disc prior to the administration. 
     
     
         8 . (canceled) 
     
     
         9 . The method according to  claim 1 , wherein the administration comprises intradiscal injection. 
     
     
         10 . The method according to  claim 9 , comprising administration into the nucleus pulposus (NP) or the annulus fibrosus (AF).

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.